The role of the NOS-ADMA-DDAH1 pathway in adipocytes and obesity
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) which is metabolised by two isoforms of the enzyme dimethylarginine dimethylaminohydrolase (DDAH). Inhibition of DDAH has been shown to increase ADMA concentrations both in vitro and in vivo. Clinically, hig...
Main Author: | Dowsett, Laura Bethany |
---|---|
Other Authors: | Leiper, James |
Published: |
Imperial College London
2013
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.656488 |
Similar Items
-
The role of DDAH and ADMA in kidney disease
by: Tomlinson, James
Published: (2013) -
CT-1 induces angiogenesis by regulating the ADMA/DDAH Pathway
by: Zhen Zhong Zheng, et al.
Published: (2015-12-01) -
Changes in ADMA/DDAH Pathway after Hepatic Ischemia/Reperfusion Injury in Rats: The Role of Bile
by: Andrea Ferrigno, et al.
Published: (2014-01-01) -
Epigallocatechin-3-gallate ameliorates erectile function in aged rats via regulation of PRMT1/DDAH/ADMA/NOS metabolism pathway
by: Dong Chen, et al.
Published: (2017-01-01) -
Elucidation of the biochemical and physiological role of DDAH2
by: Kelly, P. D.
Published: (2011)